Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004)
复制标题
DOI：
10.1016/j.diagmicrobio.2006.05.009
复制
发表时间：
2007-01-01
影响因子：
2.9
通讯作者：
Fritsche, Thomas R.
中科院分区：
文献类型：
--
作者：
Moet, Gary J.;Jones, Ronald N.;Fritsche, Thomas R.
与皮肤和软组织感染（SSTI）相关的治愈的发病率和成本最近变得更加复杂，因为与这种医疗保健问题相关的多药耐药病原体的流行率越来越高。SENTRY抗菌素监测项目自1997年以来一直在监测SSTI，目前提供了三大洲7年期间（1998-2004年）的数据。在中心实验室使用临床和实验室标准化研究所（原国家临床实验室标准委员会）方法和解释标准，通过参考肉汤微量稀释法检测分离株。主要病原体包括金黄色葡萄球菌（在所有地理区域中排名第1）、铜绿假单胞菌、大肠埃希菌和肠球菌属。耐甲氧西林（苯唑西林）的S。金黄色葡萄球菌感染率在国家和大洲之间存在差异，北美的总体感染率最高（35.9%），其次是拉丁美洲（29.4%）和欧洲（22.8%）。万古霉素耐药肠球菌属在此期间，欧洲（4.1%）和北美（6.2%）有所增长，但拉丁美洲保持较低且相对不变。在检测的铜绿假单胞菌分离株中，拉丁美洲（65.3%）对亚胺培南的敏感性远低于其他地区（80.7-88.7%），耐药性与拉丁美洲和一些欧洲国家产金属β-内酰胺酶菌株的增加有关。与欧洲（10.8%）或北美（3.2%）相比，拉丁美洲（24.7%）的铜绿假单胞菌多重耐药菌株也更令人担忧。拉丁美洲产超广谱β-内酰胺酶菌株的发生率也最高。大肠埃希菌（15.1%）和克雷伯菌属（15.1%）。(48.0与其他地区相比，继续监测病原体的流行和抗菌药物耐药性模式应提供信息，这是重要的，以改善经验性护理，特别是在医院环境。(c)2007年爱思唯尔公司All rights reserved.
The morbidity and cost for cure associated with skin and soft tissue infections (SSTIs) have recently become more complicated because of the increasing prevalence of multidrug-resistant pathogens associated with this healthcare problem. The SENTRY Antimicrobial Surveillance Program has been monitoring SSTI since 1997, and now presents data from 3 continents over a 7-year period (1998-2004). Isolates were tested by reference broth microdilution methods at a central laboratory using the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) methods and interpretative criteria. The predominant pathogens included Staphylococcus aureus (ranked 1st in all geographic regions), Pseudomonas aeruginosa, Escherichia coli, and Enterococcus spp. A considerable variation in the methicillin (oxacillin)-resistant S. aureus rate was noted between countries and continents, with the overall rate highest in North America (35.9%) compared with Latin America (29.4%) and Europe (22.8%). Vancomycin-resistant Enterococcus spp. increased in Europe (4.1%) and North America (6.2%) during the period, but remained low and relatively unchanged in Latin America. Among the P. aeruginosa isolates tested, susceptibility to imipenem was much lower in Latin America (65.3%) compared with the other region, (80.7-88.7%), and resistance being associated with an increase in metallo-p-lactamase-producing strains in Latin America and in some European countries. Multidrug-resistant strains of R aeruginosa were also more of a concern in Latin America (24.7%) compared with Europe (10.8%) or North America (3.2%). Latin America also had the highest occurrence of extended-spectrum beta-lactamase-producing isolates among E. coli (15.1%) and Klebsiella spp. (48.0%) when compared with other regions. Continued surveillance of pathogen prevalence and antimicrobial resistance patterns should provide information that is important to improve empiric care particularly in the hospital environment. (c) 2007 Elsevier Inc. All rights reserved.